PMID- 22507762
OWN - NLM
STAT- MEDLINE
DCOM- 20130121
LR  - 20190402
IS  - 1878-4216 (Electronic)
IS  - 0278-5846 (Linking)
VI  - 38
IP  - 2
DP  - 2012 Aug 7
TI  - Psychotropic drug effects on gene transcriptomics relevant to Parkinson's 
      disease.
PG  - 107-15
LID - 10.1016/j.pnpbp.2012.03.011 [doi]
AB  - OBJECTIVES: Psychotropic drugs are widely prescribed in Parkinson's disease (PD) 
      without regard to their pathobiological effects, and these drugs affect the 
      transcription of a large number of genes. Effects of these drugs on PD risk gene 
      transcription were therefore surveyed. METHODS: Results summarize a comprehensive 
      survey of psychotropic effects on messenger ribonucleic acid (mRNA) expression 
      evident in published data for 70 genes linked to PD risk. RESULTS: Psychotropic 
      drugs can meaningfully affect PD risk gene mRNA transcription, including 
      antipsychotics (upregulate dopamine receptors D2 and D3 (DRD2, DRD3); 
      downregulate low-density lipoprotein receptor-related protein 8 (LRP8), ubiquitin 
      carboxyl-terminal esterase L1 (UCHL1, also known as PARK5)), haloperidol 
      (upregulates DRD3, parkin (PRKN, also known as PARK2), DRD2; downregulates 
      brain-derived neurotrophic factor (BDNF)), risperidone (upregulates monoamine 
      oxidase B (MAOB), DRD2), olanzapine (upregulates transmembrane protein 163 
      (TMEM163), BDNF, glutathione S-transferase mu 1 (GSTM1), MAOB, DRD2, solute 
      carrier organic anion transporter family, member 3A1 (SLCO3A1)), aripiprazole 
      (upregulates DRD2), quetiapine, paliperidone, lurasidone, carbamazepine, and many 
      antidepressants (upregulate BDNF), lithium and bupropion (downregulate BDNF), 
      amitriptyline (upregulates DRD3, DRD2), imipramine (upregulates BDNF, DRD3, 
      DRD2), desipramine (upregulates BDNF, DRD3), and fluoxetine (upregulates acid 
      beta-glucosidase (GBA), coiled-coil domain containing 62 (CCDC62), BDNF, DRD3, 
      UCHL1, unc-13 homolog B (UNC13B), and perhaps huntingtin interacting protein 1 
      related (HIP1R); downregulates microtubule-associated protein tau (MAPT), 
      methylcrotonoyl-coenzyme A carboxylase I (MCCC1), GSTM1, 28kDa calbindin 1 
      (CALB1)). Fluoxetine effects on BDNF and UCHL1 in GEO Profiles were statistically 
      robust. CONCLUSIONS: This report provides an initial summary and framework to 
      understand the potential impact of psychotropic drugs on PD-relevant genes. 
      Antipsychotics and serotoninergic antidepressants may potentially attenuate PD 
      risk, and lithium and bupropion may augment risk, through MAPT, GBA, CCDC62, 
      HIP1R, BDNF, and DRD2 transcription, with MAPT, GBA, and CCDC62 being strongly 
      associated with PD risk in recent meta-analyses. Limitations of these findings 
      and a research agenda to better relate them to the nigrostriatum and PD are 
      discussed.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Lauterbach, Edward C
AU  - Lauterbach EC
AD  - Department of Psychiatry and Behavioral Sciences, Mercer University School of 
      Medicine, Macon, GA 31201, USA. eclbgnp@earthlink.net
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120403
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Psychotropic Drugs)
RN  - 0 (UCHL1 protein, human)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 2.3.2.27 (parkin protein)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
SB  - IM
MH  - Humans
MH  - Parkinson Disease/drug therapy/*genetics
MH  - Psychotropic Drugs/*pharmacology
MH  - Transcriptome/*drug effects
MH  - Ubiquitin Thiolesterase/genetics
MH  - Ubiquitin-Protein Ligases/genetics
EDAT- 2012/04/18 06:00
MHDA- 2013/01/23 06:00
CRDT- 2012/04/18 06:00
PHST- 2012/02/09 00:00 [received]
PHST- 2012/03/26 00:00 [revised]
PHST- 2012/03/26 00:00 [accepted]
PHST- 2012/04/18 06:00 [entrez]
PHST- 2012/04/18 06:00 [pubmed]
PHST- 2013/01/23 06:00 [medline]
AID - S0278-5846(12)00068-1 [pii]
AID - 10.1016/j.pnpbp.2012.03.011 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):107-15. doi: 
      10.1016/j.pnpbp.2012.03.011. Epub 2012 Apr 3.